Kadmon Holdings, Inc.

Kadmon Holdings, Inc.: May 30 PDUFA data for belumosudil (cGVHD) following positive primary analysis results (May 2020); observed ORRs of 73% and 74% in 200mg QD and 200mg BID arms, respectively. Initiating 12-15 pt open-label Ph 2 in patients w diffuse cutaneous systemic sclerosis in Q1 2021. First 3-pt dose cohort successfully completed in ongoing dose-escalation Ph 1 (anti-PD-L1/IL-15 fusion protein) in patients w metastatic or locally advanced solid tumors; enrollment ongoing in next dose level. Continuing IND-enabling activities of KD045, Kadmon's next-gen ROCK inhibitor for treatment of fibrotic diseases.

Sector/Industry:

Healthcare/Biotechnology

Characteristics:

Based in...

US - Middle Atlantic

Clinical Stage

Phase III

Disease Space

Autoimmune, Fibrosis, Immunotherapy, Oncology

Industry

Biotechnology, Pharmaceuticals

Listing

Public, USA

Market Cap

500MM - 1B

Website:

http://kadmon.com/

Profiles:

Address:

450 East 29th Street
New York, NY 10016
United States

Presentation:

Please reach out to Solebury Trout to request a presentation

More info:

Send Message to Request Information

My account:

Company Participants at Solebury Trout CEO & Investor Ski Conference 2020

Ellen Cavaleri, Investor Relations
Harlan W. Waksal, MD, President/CEO
Steve Meehan, CFO

Lead Programs

KD025

Indication	Phase
Chronic Graft-Versus-Host Disease	2
Systemic Sclerosis	2
Idiopathic Pulmonary Fibrosis	2

KD034

Indication	Phase
Wilson’s Disease	3

Top 10 Holders of Kadmon Holdings Inc Warrant 2017-28.09.22 On Kadmon Hldngs

Institution	OS (%)	Position	Mkt Val ($MM)	Source	Filing Date
The Vanguard Group, Inc.	0.00	0	0.00	Funds	10/31/20
Sofinnova Ventures, Inc.	0.00	0	0.00	13F	9/30/20

Top 10 Holders of Kadmon Holdings, Inc.

Institution	OS (%)	Position	Mkt Val ($MM)	Source	Filing Date
Perceptive Advisors LLC	9.84	15,711,334	75.73	13F	9/30/20
Consonance Capital Management LP	8.78	14,007,548	67.52	13F	9/30/20
Point72 Asset Management LP	5.67	9,049,800	43.62	Stakes	1/13/21
Avidity Partners Management LP	5.66	9,030,000	43.52	13F	9/30/20
The Vanguard Group, Inc.	5.59	8,922,790	43.01	Funds	12/31/20
State Street Corp.	5.41	8,635,710	41.62	13F	9/30/20
Vanguard Group, Inc. (Subfiler)	5.25	8,385,658	40.42	13F	9/30/20
Third Point LLC	4.76	7,601,115	36.64	13F	9/30/20
Citadel LP	4.13	6,587,531	31.75	13F	9/30/20
Boxer Capital LLC	3.89	6,205,882	29.91	13F	9/30/20

Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...

Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.